Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601752 · ClinicalTrials.gov registry record · Phase 2
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
A Phase 2 study of Ovarian Cancer, sponsored by Uswm CT.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT05601752: Active Phase 2 study of Ovarian Cancer, sponsored by Uswm CT.
NCT05601752 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 66 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05601752, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Primary Outcome
Overall Response (OR) is defined as incidence of (confirmed) complete responses or partial responses as assessed by RECIST v1.1 by IRAC from T-cell infusion until documented disease progression
Conditions Studied
Interventions
- GENETIC Autologous genetically modified ADP-A2M4CD8 cells
- COMBINATION_PRODUCT Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Study Locations (20)
Other
- Centre Leon-Berard - Lyon
- Institut de Cancerologie de Strasbourg - Strasbourg
- Institut Gustave Roussy - Villejuif
- Vall d'Hebron Unversity Hospital - Barcelona
- Clinica Universidad de Navarra - Madrid
- Hospital Universitario Ramón y Cajal - Madrid
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Centro Oncologico Clara Campal - Madrid
Arizona
- Honor Health - Scottsdale
California
- City of Hope - Duarte
Georgia
- Augusta University - Augusta
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Rutgers Cancer Institute of NJ - New Brunswick
Ohio
- Cleveland Clinic Foundation - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2026-08-12 |
| Phase | Phase 2 |
What the registry record for NCT05601752 still lists
NCT05601752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Autologous genetically modified ADP-A2M4CD8 cells is the first listed.
NCT05601752 names 20 study sites across 12 states, led by Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05601752 about?
NCT05601752 is a clinical study titled "ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)". This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
What is the current status of trial NCT05601752?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2023-06-26. Estimated completion is 2026-08-12.
What conditions does trial NCT05601752 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT05601752?
The interventions under investigation include: Autologous genetically modified ADP-A2M4CD8 cells (GENETIC), Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05601752?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05601752 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05601752's enrollment target sits among peer trials
66 186th of 322 higher than 137 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI